CMND — Clearmind Medicine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1892500 ·
Last close
$0.80
Market Cap
$1.19M
52W High
$480.00
52W Low
$0.77
ADV30
824,737
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -2,179,875 | -907,291 | 16,911,786 | 12,035,210 | 3,960,882 |
| Apr 2026 | 0 | — | -1,571,209 | -2,047,653 | 14,523,512 | 11,415,719 | 3,032,771 |
| Jan 2026 | 0 | — | -3,659,915 | -3,854,583 | 11,143,419 | 9,257,766 | 2,905,011 |
| Oct 2025 | 0 | — | -1,456,258 | -687,842 | 6,083,052 | 3,923,058 | 4,890,456 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,223,694
Investing CF
$-1,061,480
Financing CF
$14,223,192
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-202.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-33,781,960
Inventory
—
Receivables
$551,693
ST Investments
$2,177,460
EBIT TTM
$-7,874,653
Pretax Income TTM
$-7,885,947
Interest Exp TTM
$11,294
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -5,667,177 | -3,856,983 | 6,083,052 | 4,890,456 | 1,192,596 | -4,734,498 |
| Oct 2024 | 0 | -5,744,925 | -5,254,678 | 7,255,414 | 4,147,862 | 3,107,552 | -4,858,659 |
| Oct 2023 | 0 | -6,303,434 | -8,620,837 | 5,953,288 | 4,969,816 | 983,472 | -6,301,472 |
| Oct 2022 | 0 | -6,251,431 | -6,894,868 | 826,415 | 1,932,413 | -1,105,998 | -3,724,494 |
| Oct 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CDT | CDT Equity Inc. | $1.10M | $0.08 | — |
| SKVI | SKINVISIBLE, INC. | $1.09M | $0.20 | — |
| EVFM | Evofem Biosciences, Inc. | $1.06M | $0.01 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $1.40M | $0.77 | — |
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 13:05 · Yahoo
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 12:35 · Yahoo
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 11:57 · Yahoo
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
2026-09-17 11:42 · Yahoo
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
2026-09-11 12:00 · Yahoo
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million
2026-09-04 13:55 · Yahoo
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
2026-09-04 11:32 · Yahoo
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
2026-09-01 11:37 · Yahoo
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
2026-08-24 12:03 · Yahoo
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
2026-08-13 11:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.